Showing 1 - 14 results of 14 for search 'Scott S. Tykodi', 查询时间: 0.06s Refine Results
  1. 1
    Editorial: Immune checkpoint inhibitors in renal cell carcinoma

    Editorial: Immune checkpoint inhibitors in renal cell carcinoma 由 Scott S. Tykodi, Renate Pichler

    出版 2023-04-01
    获取全文
    文件
  2. 2
    Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors

    Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors 由 Yuexin Xu, Chris P. Miller, Scott S. Tykodi, Scott S. Tykodi, Shreeram Akilesh, Shreeram Akilesh, Edus H. Warren, Edus H. Warren

    出版 2024-04-01
    获取全文
    文件
  3. 3
    Belzutifan for the treatment of renal cell carcinoma

    Belzutifan for the treatment of renal cell carcinoma 由 Xiancheng Wu, David Lazris, Risa Wong, Scott S. Tykodi

    出版 2025-02-01
    获取全文
    文件
  4. 4
    Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

    Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma 由 Yuexin Xu, Chris P. Miller, Edus H. Warren, Scott S. Tykodi

    出版 2021-07-01
    获取全文
    文件
  5. 5
    Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes

    Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded cl... 由 Yuexin Xu, Alicia J. Morales, Andrea M. H. Towlerton, Shreeram Akilesh, Shreeram Akilesh, Chris P. Miller, Chris P. Miller, Scott S. Tykodi, Scott S. Tykodi, Edus H. Warren, Edus H. Warren, Edus H. Warren

    出版 2022-09-01
    获取全文
    文件
  6. 6
    Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system

    Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system 由 Chris P. Miller, Megan Fung, Carla A. Jaeger-Ruckstuhl, Yuexin Xu, Edus H. Warren, Shreeram Akilesh, Scott S. Tykodi

    出版 2023-12-01
    获取全文
    文件
  7. 7
    Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab

    Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab 由 Jonathan Zalevsky, Stanley R Riddell, Scott S Tykodi, Joshua R Veatch, Naina Singhi, Brenda Jesernig, Kelly G Paulson, Ernesto Iacucci

    出版 2020-10-01
    获取全文
    文件
  8. 8
    610 ImmunoRad: a stratified phase II trial of image guided hypofractionated radiotherapy with concurrent nelfinavir & PD-1 inhibition in advanced melanoma, lung cancer & renal cell carcinoma

    610 ImmunoRad: a stratified phase II trial of image guided hypofractionated radiotherapy with concurrent nelfinavir & PD-1 inhibition in advanced melanoma, lung cancer & renal cell... 由 Shailender Bhatia, Ramesh Rengan, Sylvia M Lee, Scott S Tykodi, Jing Zeng, Mary Redman, Peter H Goff, Kelsey K Baker

    出版 2023-11-01
    文件
  9. 9
    Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

    Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma 由 Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry V. Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin

    出版 2022-08-01
    获取全文
    文件
  10. 10
    Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

    Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma 由 Chung-Wei Lee, Thomas Powles, Sabina Signoretti, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang

    出版 2022-12-01
    获取全文
    文件
  11. 11
    Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

    Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial 由 Thomas Hutson, Peter Van Veldhuizen, Michael R Harrison, Scott S Tykodi, Daniel J George, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Ivor Percent, Rakesh Singal, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty

    出版 2022-02-01
    获取全文
    文件
  12. 12
    Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

    Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, p... 由 Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson

    出版 2022-09-01
    获取全文
    文件
  13. 13
    Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

    Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition 由 Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott

    出版 2019-02-01
    获取全文
    文件
  14. 14
    Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random... 由 Howard Gurney, Thomas Powles, Asim Amin, Bohuslav Melichar, Camillo Porta, David F McDermott, Toni K Choueiri, Marc-Oliver Grimm, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Hans J Hammers, Saby George, Robert J Motzer, Alain Ravaud, Osvaldo Arén Frontera, Frede Donskov, Philippe Barthélémy, Viktor Grünwald, Victoria Neiman, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Raya Leibowitz-Amit, Poul F Geertsen, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir

    出版 2020-10-01
    获取全文
    文件

检索工具: